Literature DB >> 9140117

Antitumor activity of TZT-1027, a novel dolastatin 10 derivative.

M Kobayashi1, T Natsume, S Tamaoki, J Watanabe, H Asano, T Mikami, K Miyasaka, K Miyazaki, M Gondo, K Sakakibara, S Tsukagoshi.   

Abstract

Dolastatin 10, a pentapeptide isolated from the marine mollusk Dolabella auricularia, has antitumor activity. TZT-1027, a dolastatin 10 derivative, is a newly synthesized antitumor compound. We evaluated its antitumor activity against a variety of transplantable tumors in mice. Intermittent injections of TZT-1027 were more effective than single or repeated injections in mice with P388 leukemia and B16 melanoma. Consequently, TZT-1027 shows schedule dependency. TZT-1027 was effective against P388 leukemia not only when administered i.p., but also when given i.v. However, although TZT-1027 given i.v. was active against murine solid tumors, TZT-1027 administered i.p. was ineffective against all the tumors tested with the exception of colon 26 adenocarcinoma. The i.v. injection of TZT-1027 at a dose of 2.0 mg/kg remarkably inhibited the growth of three murine solid tumors; colon 26 adenocarcinoma, B16 melanoma and M5076 sarcoma, with T/C values of less than 6%. The antitumor activities of TZT-1027 against these tumors were superior or comparable to those of the reference agents; dolastatin 10, cisplatin, vincristine, 5-fluorouracil (5-FU) and E7010. In experiments with drug-resistant P388 leukemia, TZT-1027 showed good activity against cisplatin-resistant P388 and moderate activity against vincristine- and 5-fluorouracil-resistant P388, but no activity against adriamycin-resistant P388. TZT-1027 was also effective against human xenografts, that is, tumor regression was observed in mice bearing MX-1 breast and LX-1 lung carcinomas. TZT-1027 at 10 microM almost completely inhibited the assembly of porcine brain microtubules. Therefore, its mechanism of antitumor action seems to be, at least in part, ascribable to the inhibition of microtubule assembly. Because of its good preclinical activity, TZT-1027 has been entered into phase I clinical trials.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9140117      PMCID: PMC5921373          DOI: 10.1111/j.1349-7006.1997.tb00383.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


median survival time increase in life span 2.morpholinoethanesulfonic acid dithiothreitol vincristine cisplatin 5.Auorouracil adriamycin vinblastine P‐glycoprotein
  27 in total

1.  Mechanism of inhibition of cell proliferation by Vinca alkaloids.

Authors:  M A Jordan; D Thrower; L Wilson
Journal:  Cancer Res       Date:  1991-04-15       Impact factor: 12.701

2.  Phase-II study of Navelbine in advanced breast cancer.

Authors:  L Canobbio; F Boccardo; G Pastorino; F Brema; C Martini; M Resasco; L Santi
Journal:  Semin Oncol       Date:  1989-04       Impact factor: 4.929

3.  Microtubule assembly in the absence of added nucleotides.

Authors:  M L Shelanski; F Gaskin; C R Cantor
Journal:  Proc Natl Acad Sci U S A       Date:  1973-03       Impact factor: 11.205

4.  Comparative study of in vivo development of resistance to various classes of antitumor agents in P388 leukemia.

Authors:  M Inaba; R Fujikura; Y Sakurai
Journal:  Gan       Date:  1979-10

5.  LU103793 (NSC D-669356): a synthetic peptide that interacts with microtubules and inhibits mitosis.

Authors:  M de Arruda; C A Cocchiaro; C M Nelson; C M Grinnell; B Janssen; A Haupt; T Barlozzari
Journal:  Cancer Res       Date:  1995-07-15       Impact factor: 12.701

Review 6.  Multidrug-resistance phenotype in Chinese hamster ovary cells.

Authors:  V Ling; N Kartner; T Sudo; L Siminovitch; J R Riordan
Journal:  Cancer Treat Rep       Date:  1983-10

7.  Experimental antitumor activity of 5'-nor-anhydrovinblastine navelbine.

Authors:  R Maral; C Bourut; E Chenu; G Mathé
Journal:  Cancer Lett       Date:  1984-02       Impact factor: 8.679

8.  Dolastatin 15, a potent antimitotic depsipeptide derived from Dolabella auricularia. Interaction with tubulin and effects of cellular microtubules.

Authors:  R Bai; S J Friedman; G R Pettit; E Hamel
Journal:  Biochem Pharmacol       Date:  1992-06-23       Impact factor: 5.858

9.  Responsiveness of human lung cancer/nude mouse to antitumor agents in a model using clinically equivalent doses.

Authors:  T Tashiro; M Inaba; T Kobayashi; Y Sakurai; K Maruo; Y Ohnishi; Y Ueyama; T Nomura
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

10.  Active efflux of daunorubicin and adriamycin in sensitive and resistant sublines of P388 leukemia.

Authors:  M Inaba; H Kobayashi; Y Sakurai; R K Johnson
Journal:  Cancer Res       Date:  1979-06       Impact factor: 12.701

View more
  18 in total

Review 1.  Drug development from marine natural products.

Authors:  Tadeusz F Molinski; Doralyn S Dalisay; Sarah L Lievens; Jonel P Saludes
Journal:  Nat Rev Drug Discov       Date:  2008-12-19       Impact factor: 84.694

Review 2.  Marine Mollusk-Derived Agents with Antiproliferative Activity as Promising Anticancer Agents to Overcome Chemotherapy Resistance.

Authors:  Maria Letizia Ciavatta; Florence Lefranc; Marianna Carbone; Ernesto Mollo; Margherita Gavagnin; Tania Betancourt; Ramesh Dasari; Alexander Kornienko; Robert Kiss
Journal:  Med Res Rev       Date:  2016-12-07       Impact factor: 12.944

3.  First natural analogs of the cytotoxic thiodepsipeptide thiocoraline A from a marine Verrucosispora sp.

Authors:  Thomas P Wyche; Yanpeng Hou; Doug Braun; Hannah C Cohen; May P Xiong; Tim S Bugni
Journal:  J Org Chem       Date:  2011-07-20       Impact factor: 4.354

Review 4.  Marine anticancer drugs and their relevant targets: a treasure from the ocean.

Authors:  Manisha Nigam; Hafiz Ansar Rasul Suleria; Mohammad Hosein Farzaei; Abhay Prakash Mishra
Journal:  Daru       Date:  2019-06-05       Impact factor: 3.117

5.  Gene expression profiling of exposure to TZT-1027, a novel microtubule-interfering agent, in non-small cell lung cancer PC-14 cells and astrocytes.

Authors:  T Natsume; T Nakamura; Y Koh; M Kobayashi; N Saijo; K Nishio
Journal:  Invest New Drugs       Date:  2001       Impact factor: 3.850

6.  Antineoplastic agents. 592. Highly effective cancer cell growth inhibitory structural modifications of dolastatin 10.

Authors:  George R Pettit; Fiona Hogan; Steven Toms
Journal:  J Nat Prod       Date:  2011-05-02       Impact factor: 4.050

Review 7.  The expanding role of marine microbes in pharmaceutical development.

Authors:  Amanda L Waters; Russell T Hill; Allen R Place; Mark T Hamann
Journal:  Curr Opin Biotechnol       Date:  2010-10-16       Impact factor: 9.740

8.  Therapeutic potential of SGN-CD19B, a PBD-based anti-CD19 drug conjugate, for treatment of B-cell malignancies.

Authors:  Maureen C Ryan; Maria Corinna Palanca-Wessels; Brian Schimpf; Kristine A Gordon; Heather Kostner; Brad Meyer; Changpu Yu; Heather A Van Epps; Dennis Benjamin
Journal:  Blood       Date:  2017-09-13       Impact factor: 22.113

9.  Bombesin marine toxin conjugates inhibit the growth of lung cancer cells.

Authors:  Terry W Moody; Tapas Pradhan; Samuel A Mantey; Robert T Jensen; Marcin Dyba; Deborah Moody; Nadya I Tarasova; Christopher J Michejda
Journal:  Life Sci       Date:  2008-02-14       Impact factor: 5.037

10.  The novel microtubule-interfering agent TZT-1027 enhances the anticancer effect of radiation in vitro and in vivo.

Authors:  Y Akashi; I Okamoto; M Suzuki; K Tamura; T Iwasa; S Hisada; T Satoh; K Nakagawa; K Ono; M Fukuoka
Journal:  Br J Cancer       Date:  2007-05-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.